Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
Abbas
Ume L
UL
Division of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Mellors
John W
JW
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D012307:Risk Factors
D019380:Anti-HIV Agents; D012367:RNA, Viral